ArticleRare tumors2026
Burden and unmet needs of liposarcoma in the United States: Patient perspectives on the liposarcoma diagnostic journey.
Article in Rare tumors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Studies investigating the impact of liposarcoma from the patient's perspective-including diagnosis, disease presentation, treatment challenges, and quality of life (QOL)-are limited. We report findings from a survey of patients with liposarcoma evaluating the diagnostic/treatment journey, biomarker testing, and QOL. Methods: Patients with liposarcoma in the United States completed an online survey assessing demographics, diagnostic journey, disease burden, treatment, QOL, and sources of support during diagnosis and treatment. Descriptive statistical analyses were performed, and qualitative written responses from participants were assessed. Results: Seventy-seven patients with liposarcoma participated in the survey. The proportion of participants with stage I/II/III/IV/unknown liposarcoma at diagnosis was 22%/16%/26%/13%/23%, respectively. Within 12 months of symptom onset, 44/60 respondents (73%) saw a medical professional, and 39/77 (51%) first consulted an internal medicine specialist. Fifty-one of 77 participants (66%) were aware of biomarker testing, and 32/51 (63%) reported receiving it. The most common initial treatments were surgery (47/77, 61%), radiotherapy (15/77, 19%), and chemotherapy (9/77, 12%). Health insurance provided coverage for biomarker testing for 27/31 respondents (87%). Of 77 participants, 38 (49%) traveled ≥1 hour to reach their treatment site, and 27 (35%) relied on care partners such as family members for transportation. Upon treatment initiation, QOL improved for 30/77 participants (39%), did not improve for 29/77 (38%), and 10/77 (13%) were unsure. Forty participants (52%) used social media to obtain disease-specific information and support. Conclusion: Our survey identified gaps in patients' awareness and understanding of key aspects of liposarcoma diagnosis and treatment, highlighting a need for better patient education, more effective communication between medical professionals and patients, and a deeper understanding of how treatment impacts patients' QOL. A fuller picture of the patient burden due to liposarcoma underscores the need for research aimed at improving symptom and disease management, including the development of more effective therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.